MAPT and type 2 diabetes mellitus: Given that T2DM is characterized by insulin resistance, hyperinsulinemia and impaired insulin signaling, it is not surprising that the increased GSK-3β activity in T2DM may lead to an increase in Aβ production and increase tau phosphorylation.